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Abstract:
Hereditary neuropathy with liability to pressure palsies (HNPP) and Charcot-MarieTooth Disease type 1A (CMT1A) are autosomal dominant hereditary neuropathies caused by
different mutations in the PMP22 gene. The chronic features of CMT1A and HNPP are almost
identical, leaving electrodiagnostic testing to assess nerve conduction as the vital distinguisher
between these two diagnoses. Differing onset, duration and recovery, as well as genetic testing,
can also help distinguish the diagnosis. Patients with CMT1A often have chronic and
progressively worsening symptoms, whereas patients with HNPP experience transient, acute
symptoms that may or may not be associated with pain and with possible milder and later onset
chronic progressive symptoms. The intent of this study is to address the hypothesis that the
intermittent pattern of symptoms is the reason for worse QOL observed in HNPP patients as
compared to CMT1A, as well as to establish other potential reasons behind differing perceptions
in quality of life between CMT1A and HNPP patients. A questionnaire consisting of nine Likert
scaled questions, four binary questions, and four questions with an open-ended component was
distributed to hereditary neuropathy associations and support groups. A total of 287 individuals
with CMT1A and 84 individuals with HNPP completed the survey. Data analysis was performed
using the “R” platform for statistical computing and subsequent application of Welch's TwoSample T-Test. Our results support an argument in opposition to the original hypothesis,
concluding that CMT1A and HNPP patients with chronic symptoms spend more time worrying
about their symptoms, thereby negatively impacting their QOL. There are many confounding
medical, social and psychological factors associated with chronic disease and pain that could be
the true reason behind worse QOL reports. Further research using quality of life assessments,
taking into account patient demographics and ascertainment biases, can guide how healthcare

providers, including general practitioners, genetic counselors and rehabilitative specialists,
modify patient management throughout the diagnostic and treatment processes in order to
improve quality of life in this population.
Keywords: Charcot-Marie-Tooth Disease, CMT1A, Hereditary Neuropathy with liability to
pressure palsies, HNPP, quality of life, QOL, chronic, intermittent
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Introduction:
Hereditary neuropathy with liability to pressure palsies (HNPP) and Charcot-MarieTooth Disease (CMT) are both autosomal dominant hereditary neuropathies caused by mutations
in the PMP22 (peripheral myelin protein-22) gene (Padua et al., 2018, Beales et al., 2017).
CMT1A is the most frequent subtype of CMT and is the result of a duplication of PMP22,
whereas HNPP is caused by a deletion of the PMP22 gene, resulting in a predisposition to focal
compression neuropathies (Padua et al., 2018, Beales et al., 2017). PMP22 is a gene that plays an
important role in Schwann cell growth and differentiation, explaining why symptoms involving
the nervous system are prevalent (Van Paassen et al., 2014). The features of CMT1A and HNPP
are almost identical, leaving the onset, duration, and recovery of symptoms as vital distinguishers
between these two diagnoses. One major difference in how the two syndromes present clinically:
patients with CMT1A often have chronic and progressively worsening symptoms, whereas
patients with HNPP experience transient, acute symptoms that may or may not be associated
with pain, in addition to possible chronic progressive symptoms although often milder and with
later onset than seen in CMT1A. Establishing the reasons behind differing perceptions in quality
of life between CMT1A and HNPP patients is vital for understanding how to improve healthcare
management and patient satisfaction for these patient populations.
Charcot-Marie-Tooth disease type 1A (CMT1A) makes up the most common form of
hereditary neuropathies with an estimated prevalence ranging from 1/2500 to 1/1200 (Friedman et
al., 2005). CMT1A is characterized by distal muscle weakness, sensory loss, foot deformities,
decreased or absent tendon reflexes, muscle wasting, and reduced nerve conduction velocities.
Duplications in PMP22 result in increased levels of PMP22 expression, causing instability in the
structure of the compact myelin. This instability causes axonal degeneration as the axons
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repeatedly demyelinate, remyelinate and undergo onion bulb formation as a result of Schwann cell
accumulation (Murakami, 2019). CMT1A is a chronic, progressive disease and develops slowly;
once the symptoms develop, they remain and may become worse (Johnson et al., 2014). CMT1 is
clinically diagnosed based on the following criteria: a slowly progressive peripheral motor and
sensory neuropathy, slow nerve conduction velocity and a family history consistent with autosomal
dominant inheritance. Other supporting evidence includes palpably enlarged nerves or onion bulb
pathology on nerve biopsy. (Bird, 2015). A clinical diagnosis can be confirmed with molecular
genetic testing using either a serial single gene approach or a multigene panel. Being that CMT1A
is the most common type of CMT1, accounting for 70-80% of cases, providers may choose to
initiate genetic testing with the PMP22 duplication first, followed by the genes associated with
other CMT1 subtypes if initial testing is negative.
Patients with HNPP experience a heterogeneous array of clinical features that often overlap
with those experienced by patients with CMT1A, including distal muscle weakness, muscular
atrophy, sensory loss and episodes of pain (Beales et al., 2017, Van Paassen et al., 2014). The
clinical features considered in establishing a diagnosis of HNPP include painless attacks of
numbness and/or loss of motor function (nerve palsy), often preceded by minor compression on a
nerve; onset of symptoms typically between the ages of 20 and 30; pes cavus (seen in 4-47% of
patients); and recovery from nerve palsies about 50% of the time within days to weeks of onset
(Van Paassen et al., 2014). The symptoms observed in affected family members may differ from
those reported in the patient due to the variable expressivity associated with HNPP (Van Paassen
et al., 2014). In contrast to CMT1A, the symptoms experienced by patients with HNPP are often
of an intermittent nature, resolving within days to weeks, as opposed to being chronic and
worsening.
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The criteria used to establish a diagnosis of HNPP includes clinical criteria,
electrophysiological criteria, neuropathological features and molecular genetics (Dubourg et al.,
2000). Clinical criteria include autosomal dominant inheritance pattern observed in the family
history; a range of clinical manifestations, such as recurrent and regressive peripheral nerve
palsies, sensory and motor deficits and episodes of pain; and intermittent nature of symptoms.
Electrophysiological criteria include presence of diffuse electrophysiological abnormalities, such
as reduced or delayed MNCV (motor nerve conduction velocity) in one of the peroneal nerves, at
the elbow or in the lower limbs, and reduced sensory nerve action potentials in the upper limbs
(Dubourg et al., 2000). Neuropathology typically shows large, focal thickening of the myelin
sheaths, and molecular genetic testing reveals the 17p11.2 deletion in 80-90% of HNPP patients
(Dubourg et al., 2000). These criteria are evaluated in conjunction with one another, as well as in
the context of genetic testing results. Other genetic alterations involving the PMP22 gene have
been reported, including point mutations, very small deletions and translocations, that also result
in symptoms consistent with a diagnosis of HNPP (Bellone, 2006; Nadal, 2000; Fusco, 2017; van
de Wetering, 2002). Kumar et al documented the wide range of phenotypic variability observed in
a small cohort of patients with HNPP (Kumar et al., 2002). Clinical symptoms, as well as
electrophysiological data, showed marked variability, including compressive neuropathy (seen
most commonly), brachial paralysis, confluent mononeuropathy multiplex and polyneuropathy.
Additionally, a large portion of patients were experiencing few to no symptoms (Kumar et al.,
2002). This study highlights the complexities of a rare disease such as HNPP, as it can often be
difficult to pinpoint a diagnosis in light of the broad variation of presenting features that may
overlap with other conditions.
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Pain is a symptom that has not historically been characterized as a symptom of HNPP
(Dubourg et al., 2000). However, more recent studies have identified that some patients do, in fact,
experience episodes of pain along with their other symptoms (Beales et al., 2017). Beales et al.
obtained information about the type of pain experienced by individuals with HNPP, as well as how
this impacted their activities of daily living and their perception of whether or not their diagnosis
is the cause of their pain (Beales et al., 2017). Patients with HNPP reported details about the
clinical presentation of their pain, leading Beales et al. to classify the pain as neuropathic pain
resulting from lesions or from disease of the somatosensory nervous system and pain related to
central sensitization (Beales et al., 2017). The validity and reliability of the questionnaires used in
the Beales study has not yet been directly established with respect to their use for patients with
HNPP. However, this study did suggest that pain is a symptom directly related to a diagnosis of
HNPP and should be included as a primary symptom when evaluating an individual for HNPP.
Understanding the implications associated with pain, both physical and psychological, and
acknowledging the complexity of pain severity and frequency is vital to ascertaining the impact
pain has on the patient. Many studies have addressed pain as a singular symptom and have not
taken into account the underlying implications that could be causing a patient’s reports of poor
quality of life. A focus on how pain interferes with a patient’s activities of daily living is a main
arm of the experience of pain that deserves attention among CMT1A and HNPP groups. Pain
triggers significant loss of daily function, making it difficult to think about or accomplish anything
else (Eccleston et al., 2013). Pain overwhelms other concerns and may cause an individual to
establish new behavioral and motivational priorities. For instance, for patients with both HNPP
and CMT1A, efforts to manage the anxiety associated with when an episode may arise can become
a major, daily focus, preventing them from focusing on other activities of daily living. The Fear4

Avoidance Model of Chronic Pain hypothesized that anxiety amplifies the intensity of emotional
reactions and the tendency to avoid activities, which contributes to the development and
maintenance of chronic pain (Romeo et al., 2017). According to this model, catastrophic thinking
and the fear of certain movements lead to the maintenance of fear and hypervigilance in relation
to bodily sensations. Additionally, high-catastrophizing patients might express their needs for
support in ways that may cause their family members to react negatively (Romeo et al., 2017).
This may lead high-catastrophizing patients in the HNPP and CMT1A community to join support
groups to replace the relationships lost or strained due to these tendencies. This will be explored
in our Discussion section in consideration of the profiles of our participant sources (support
groups).
A study conducted by Ribiere, assessing the frequency of enduring pain associated with
CMT1A, evaluated 50 patients with a confirmed CMT1A diagnosis via genetic testing and positive
family history. The 27 females and 21 males in the study had a mean age of 46 years and were an
average of 20 years from the onset of symptoms. Pain assessment took into account the
medications the patients were on and the responses collected in the DN4 questionnaire. The DN4
questionnaire is a method of estimating the probability that an individual’s pain is neuropathic by
nature. Thirty-one of 48 individuals included in the study experienced pain for about 20 years
while the remaining 18 had not encountered pain at all. Of all the patients assessed, 66 percent had
long-lasting discomfort. Of the patients experiencing pain, 40.6% had a positive DN4 indicating
that their pain was neuropathic. In 62.5% of the cases, the pain did not have an underlying
mechanical origin. This suggests the possibility that the absence of severe electrophysiological
symptoms does not necessarily correlate with decreased pain or with improved quality of life
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perception. In fact, any pain could be associated with a report of worse quality of life as a result of
the social, emotional and anxiety-provoking impact of the pain experienced.
HNPP is a rare disorder with a known prevalence of about 16 out of 100,000 individuals
(Meretoja et al., 1997). One would think the prevalence of CMT1A and HNPP should be similar
based on the genetic mechanisms of each both involving changes in PMP22; the tandem repeats
flanking the 1.5 MB region are hotspots for recombination misalignment leading to copy number
errors (Park, et al., 2018). It is suspected that the number of individuals affected with HNPP, but
without an official diagnosis, is much greater due to the high incidence of misdiagnosis, the
transient nature of the symptoms, as well as the heterogeneity of phenotype and age of onset, with
some individuals remaining asymptomatic throughout their lifetime (Ruttenberg et al., 2018,
Kumar et al., 2002, Harada et al., 2016). The intermittent nature of the symptoms may lead to
repeat doctor visits, referrals to specialists and excessive tests or procedures, resulting in high
levels of frustration on the part of the patient. Ruttenberg et al. described a case report in which a
patient with undiagnosed HNPP was admitted to the emergency department, raising a series of
challenges for physicians who do not specialize in neurological disorders (Ruttenberg et al., 2018).
The differential diagnoses that were suspected before arriving at HNPP included central
hemorrhagic and ischemic processes, central venous thrombosis, syringomyelia, Guillain-Barre
syndrome, toxic exposure and a compressive cervical spine lesion (Ruttenberg et al., 2018). The
time, expense and unnecessary procedures performed in order to rule out these differentials are
examples of obstacles faced by healthcare providers and patients alike as a result of the difficulties
associated with diagnosing HNPP. Benzakour et al. described a patient who underwent a nerve
conduction study that revealed results that were not hallmark of HNPP, but suggested axonal
polyneuropathy, leading to a suspected differential diagnosis of diabetes mellitus or amyloidosis
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(Benzakour et al., 2018). Chronic inflammatory demyelinating polyneuropathy was initially
diagnosed based on multiple blood and electrophysiological tests, but after months of treatment
with steroids, no improvement was observed. Only after a follow-up electrophysiological study
showed bilateral ulnar motor conduction blocks at the elbows was HNPP ultimately diagnosed
(Benzakour et al., 2018). This study offers another example in which an HNPP diagnosis was
delayed due to unclear symptoms that overlapped with other, more common, conditions.
As with CMT, there is currently no cure for HNPP; treatments mainly revolve around
management of symptoms and pain. Management for the symptoms associated with HNPP focuses
primarily on avoiding positions or situations that would put pressure on the nerves, such as
prolonged sitting with legs crossed or leaning on elbows, occupations requiring repetitive
movements of the wrist and rapid weight loss (Bird, 2019). Pain medication and use of splints or
protective pads on elbows and knees to prevent pressure on the peripheral nerves are some of the
methods used to address the symptoms and resulting pain (Bird, 2019). Depending on specific
manifestations, a wrist splint may aid in alleviating carpal tunnel syndrome and ankle-foot orthoses
may alleviate foot drop (Bird, 2019). Heng et al. reported the use of steroids in treatment of HNPP
in two patients who had experienced at least 5 months of consistent symptoms. Three weeks after
administration of steroids, both patients had improved symptoms, which persisted up to 5 months
post treatment (Heng et al., 2012). It is suspected that steroid treatment was successful in these
specific patients because they had been experiencing symptoms for a long enough period of time
that inflammation was starting to have neurotoxic effects, as opposed to a healing effect. This
small case study suggests that patients who have incomplete recovery of symptoms and a more
chronic presentation may benefit from a therapeutic trial of steroids (Heng et al., 2012).
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The examples mentioned above highlight the importance of diagnosing HNPP promptly
for appropriate healthcare management and treatment of symptoms and ultimately, for patient
satisfaction with their healthcare team and their personal quality of life. Calvert et al. used the EQ5D survey to investigate the impact that rare long-term neurological conditions have on healthrelated quality of life (Calvert et al., 2013). The EQ-5D is a standardized survey used to measure
health-related quality of life in patients with a variety of health conditions. Five dimensions related
to quality of life are scored, including mobility, self-care, usual activities, pain/discomfort and
anxiety/depression, in order to reflect the patient’s own judgement and perception. Tools such as
the EQ-5D are designed in order to pinpoint aspects of a patient’s life that may be contributing to
a poor quality of life and to aid in identifying ways in which the healthcare system can support
patients in mitigating these contributing factors (Johnson et al., 2018).
Calvert et al. discovered that a lack of access to health and social care services may be the
reason behind this poor perception of quality of life (Calvert et al., 2013). Although Calvert’s study
did not specifically address patients with HNPP, this does raise a question for this group because
the intermittent nature of the symptoms creates a situation in which patients may not feel as though
they consistently need services and may discontinue services when their symptoms abate.
Additionally, the lack of a diagnosis or a misdiagnosis could prevent them from promptly getting
the consistent care they need. Ideally, a survey designed specifically for the symptoms experienced
by patients with HNPP would target the intermittent nature of the symptoms, the delay in diagnosis
due to large phenotypic variability, the number of specialists seen before arriving at a diagnosis,
the impact symptoms have on activities of daily living, and the disruption that sudden onset of
symptoms causes in a patient’s life. Grider et al. found that patients with HNPP reported lower
scores on quality of life perception than patients with CMT1A even though the patients with
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CMT1A had more severe symptoms (Grider et al., 2015). Targeting characteristics of the disease
that are specific to HNPP could help elucidate exactly what is causing a poor perception of quality
of life for these patients. This can ultimately aid in tailoring healthcare management strategies to
better support patients with HNPP in managing their intermittent symptoms.
As discussed above in regards to HNPP patients, various surveys have been used in
previous studies to aid in determining the factors associated with quality of life (QOL) among
CMT1A patients (Johnson et al., 2018, Grider et al., 2015). Johnson et al. utilized a survey
consisting of 20 themes representing 214 symptoms and used a Likert scale to measure their
findings in CMT1A patients (Johnson et al., 2018). Themes with the highest individual impact
scores were: foot and ankle weakness (2.93; SD 1.06), impaired balance (2.79; SD 1.15), and
limitations with mobility (2.69; SD 1.14). Age, symptom duration, CMT type, gender, and
employment were also included in the survey. Notably, as an individual aged, symptom prevalence
increased and QOL worsened significantly. Several themes were more prevalent in women with
CMT1A, including activity limitations, pain, fatigue, hip–thigh weakness, and gastrointestinal
issues. Qualitative interviews in the Johnson study with patients identifies the discrepancy of the
QOL reports between the HNPP and CMT1A groups by revealing difficulty with mobility and
ambulation and activity impairment as the life altering themes being the most frequently mentioned
factors by CMT1A patients. In the Stojkovic review, the same physical features that were observed
in the Johnson study, both clinical and electrophysiological, were further specified and found to
exhibit wide variability. This study was conducted by describing the specific electrophysiological
characteristics of gene-specific hereditary neuropathies, including CMT1A, and then using whole
exome sequencing to search for genes implicated in these conditions. From a quality of life
perspective, the electrophysiological severity of CMT1A had little to do with reporting a worse
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QOL. This study proved that the severity of axonal degeneration did not correlate with a worsening
of the patient’s perception of their daily life and that further variables were influencing QOL
impairment (Stojkovic, 2016). The most profound impact came from the concern of physical
function in relationship to social aspects of life (Caliandro et al., 2006).
The Burns study included demographic and symptom data, standardized measures of gross
motor function, foot/ankle and hand/finger involvement, electrophysiology, and gait
characteristics in their assignment of QOL scores. Symptoms such as fatigue and restless leg
syndrome stood out as playing a key role in CMT QOL amongst younger patients (Burns et al.,
2010). Sleep-related symptoms and restless leg syndrome were specifically explored as a possible
factor affecting quality of life amongst all CMT genotypes (Boentert et al., 2014). Fatigue, sleep
quality, daytime sleepiness, Restless leg syndrome (RLS) prevalence, RLS severity, and healthrelated QOL were not distinguishable between the different types of CMT, but were
distinguishable amongst men and women, with women being more often and more severely
affected than men. Recognizing that sleep disturbances can have a great effect on QOL, Boentert
et al. conducted another study (2016) to investigate both prevalence and severity of obstructive
sleep apnea, RLS and periodic limb movements in sleep (PLMS) in adult patients with genetically
proven CMT1A. Sixty-one patients with CMT1 and 61 insomniac control subjects were matched
for age, sex, and Body Mass Index. Neurological disability in patients with CMT was assessed
using the Functional Disability Scale, and RLS diagnosis was based on a screening questionnaire
and structured clinical interviews. Their data suggests that CMT1A patients may be predisposed
to obstructive sleep apnea and that RLS is highly prevalent amongst CMT1A groups, affecting
QOL outcomes independently of biomechanical presentation. Using the SF-36 Quality of Life
scale to evaluate 121 patients with CMT, Vinci et al. showed that patients with CMT as a group
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have significantly lower physical function and mental health function scores than the general
population of Italy as a whole. This study also identified differences between older and younger
patients, men and women, and patients in and out of work but not between patients with
demyelinating or axonal forms of CMT, further demonstrating that QOL does not invariably
correlate with disease severity (Vinci et al., 2005).
Hereditary neuropathy with liability to pressure palsies (HNPP) is a rare condition that
presents with a broad range of clinical symptoms, making it a difficult syndrome to diagnose. The
intermittent nature of the symptoms can create hesitancy from the patient in seeking healthcare
support, as well as delays in arriving at a diagnosis and ultimate symptom management. Although
approximately 80% of patients with HNPP have a deletion in the PMP22 gene, genetic testing is
traditionally only ordered based on the clinical features, family history and results from
electrophysiological tests, making it extremely important that healthcare providers are familiar
with HNPP presentation and consider it as a possibility in the differential. Accurate and prompt
diagnosis of HNPP is vital in order to ensure that healthcare management is suitable, inappropriate
surgical intervention is not performed based on a misdiagnosis, and patients are provided access
to healthcare support that matches their individual clinical presentation. Ultimate patient
satisfaction and quality of life perception hinges on correct diagnosis and adequate, prompt
management of symptoms, as well as how those symptoms are impacting activities of daily life
and social behavior. A major aspect of the genetic counseling purview surrounds providing support
for patients as they come to terms with their condition and understand the impact it may have on
their daily life. In order to ensure that we are providing the most relevant and applicable support,
genetic counselors utilize psychosocial counseling techniques to identify and address our patients’
quality of life concerns and needs. Because of this strong clinical focus, genetic counselors are in
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a unique position to contribute to research related to quality of life perception. Our study aims to:
1) compare the diagnostic odyssey between the HNPP and CMT1A groups in regard to how their
experience is impacting daily life 2) assess how the pattern and anticipation of symptoms affects
the thinking, planning, and overall quality of life of individuals with HNPP compared to
individuals with CMT1A.
2. Methods
2.1 Design
A questionnaire consisting of nine Likert scaled questions, four binary questions, and
four questions with an open-ended component were compiled using data and hypotheses from a
previously conducted QOL study on the same groups by Grider, et al. (See Appendix A). The
four binary questions (Q 5, 12, 13, 15) were intended to establish in general whether the
participant feels their QOL is impacted by the pattern of their symptoms and specifically whether
the number of doctor visits they have to regularly attend, surgeries undergone, or misdiagnosis
has played a role. If a participant responded “yes” to binary questions 13 or 15, there was an
open-ended component for the participant to specify their response. The four questions with an
open-ended option (Q 2, 3, 13, 15) asked subjects to select symptoms experienced from a list,
state their official diagnosis at the time of taking the survey, share whether they have been
misdiagnosed with another condition prior to their current diagnosis and input the types of
surgeries they have had as a result of their diagnosis. These questions were designed with the
intent to address the second hypothesis concerning diagnostic odyssey and unnecessary
procedures affecting QOL. The nine Likert scaled questions (Q 4, 6, 7, 8, 9, 10, 11, 14, 16) were
designed to assess how much importance an individual placed on the pattern and anticipation of
12

symptoms associated with their diagnosis and how the participants’ perception of their symptoms
impacts their QOL, which was not included in the Grider study.
2.2 Study Sample/Recruitment
The goal was to capture individuals with either a diagnosis of CMT1A or HNPP. Being
that HNPP is significantly rarer than CMT1A, a focus was placed on capturing as many
individuals with HNPP as possible. We sent out recruitment emails (see Appendix B) to the
leaders of associations and support groups to post the link to the survey on their websites and in
their discussion forums. The groups included the Charcot Marie Tooth Association, Muscular
Dystrophy Association, Hereditary Neuropathy Foundation, Charcot Marie Tooth Disease
Facebook Support Group, CMT US Facebook Support Group, and Charcot Marie Tooth
Facebook Group. Eligibility to take the survey was a diagnosis of CMT1A or HNPP. The first
two questions of the survey acted as a built-in filter that asked individuals what they have been
diagnosed with and which symptoms they experience. Upon starting the survey, participants
were immediately asked to review our consent form which provides details about what their
participation in the study would entail, as well as key ethical information, such as confidentiality
and their right to withdraw. Ethical approval for this study was obtained from Sarah Lawrence
College IRB. A total of 287 individuals with CMT1A and 84 individuals with HNPP completed
the survey.
2.3 Data Collection
Data was collected electronically through Survey Monkey. The average time to complete
the survey was around five minutes. The survey was open for a total of 40 days, allowing
patients from the above mentioned groups to respond. The number of responses was limited by
13

the amount of time the survey was made available. Ultimately, 287 responses from patients with
CMT1A versus 84 responses from patients with HNPP were received.
2.4 Data Analysis
Compiled data from the questionnaires for both groups was exported from Survey
Monkey. Variables were created based on question stems and responses were converted to a
spreadsheet of comma separated values which was subsequently run through an “R” script for
data wrangling, statistical computing and analysis. From the master spreadsheet, data subsets for
the CMT1A and HNPP cohorts were extracted and further divided based on characteristics of
interest using responses to specific questions (e.g. subsets of patients who needed surgery were
created based on Q15). All incomplete datasets were removed from the data analysis.
Sample means and their respective standard deviation of all Likert scaled questions were
calculated using R, whereas absolute counts and overall percentages were obtained for all binary
questions. Further analysis of the aforementioned sample means was conducted by applying
Welch’s t-test with an alpha-value of 0.05; this test was chosen due to the disparate sample sizes
between the CMT1A and HNPP cohorts and the relative superiority of Welch’s t-test as opposed
to Student’s t-test.
The data was converted into an excel spreadsheet with numerical values to represent
responses. A script was written to define the weight of each response, which was done through
the “R” platform for statistical computing. For questions 4, 6, 7, 8, 9, 10, 11, and 14, a Likert
scale approach was used to quantify answers. Welch's Two-Sample T-Test was then applied to
determine if the difference in means between the two group samples is due to chance. If the pvalue is < 0.05, then the difference between two means is unlikely to be due to chance. However,
14

Welch's T-test assumes that both samples are normally distributed, which was not the case for
question 11.
Questions 5, 12, 13, and 15 were binary (1 = yes, 2 = no). Thus, absolute counts and
overall percentages were calculated for these data.
3. Results
A total of 293 CMT1A participants completed the survey; the data of 287 were used for
analysis, with 6 omitted due to incomplete responses. Of this CMT1A subset, 140 (48.8%)
needed surgery due to their diagnosis. A total of 85 HNPP participants completed the survey; the
data of 84 were used for analysis, with 1 omitted due to incomplete responses. Of this HNPP
subset, 20 (23.8%) needed surgery due to their diagnosis.
Six of the nine Likert scaled questions revealed sample means in which CMT1A
participants, on average, reported worse QOL measures than their HNPP counterparts (Fig. 1).
Of the nine Likert scaled questions, the difference in sample means between the CMT1A and
HNPP cohorts was statistically significant for three questions: Q4, Q7, and Q8 (Fig. 2). Of the
Likert scalable questions, questions 7, 8, 9 and 10 proved to not be statistically significant (Fig.
1). However, when taking a qualitative approach, one sees a clear and consistent overall
increased concern about their symptom onset, frequency and severity from the CMT1A group
over the HNPP group. For Question 6 (Fig. 2), there was a slight statistical significance, a pvalue of 0.049, which prompted further evaluation of the data (see Figure 5). By omitting
CMT1A patients who answered for Question 4 that their pattern of symptoms were occurring
once a month or longer (intermittent) and comparing the chronic CMT1A patients with HNPP
subjects who reported intermittent pressure palsies as one of their symptoms (n=71), a clear
15

statistical significance is produced for Question 6 in opposition of the original hypothesis. This
result shows that CMT1A patients with a chronic pattern reported spending more time thinking
about their symptoms than HNPP patients that experienced pressure palsies which have an
intermittent pattern.
Absolute counts and calculated overall percentages for the four binary questions revealed
a higher reporting of negative QOL outcomes in the CMT1A cohort for Q12 and Q15, whereas a
higher percentage of the HNPP cohort reported negative QOL outcomes for Q13. The overall
percentages for Q5 were equivocal (Fig. 3).
4. Discussion
The data analysis corroborates an argument in opposition to the original hypothesis that
HNPP patients would report worse QOL outcomes because of the intermittent pattern of their
symptoms. Past QOL studies have also contrasted our results in that despite a chronic and worse
prognosis in CMT1A patients, emotional aspects seem to become less important with disease
duration (Schorling et al. 2019). The raw data suggests that on average, CMT1A patients are
reporting increased concern about experiencing symptoms. This may be due to the concern of
social withdrawal that CMT1A symptoms may cause, as demonstrated in the Caliandro et al.
study, in which the most profound impact came from the concern of physical function in relation
to social aspects of life.
The responses of the CMT1A cohort may have also been confounded by ascertainment
bias; over 50% of participants were recruited from support groups, with the CMT1A group being
more robust than the HNPP group, as evidenced by the disparate response totals for each cohort.
The Anastas study suggested that patients with chronic pain are influenced by patient and
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contextual factors when making pain-related and disability judgments. It logically follows that
support groups are a potent source of ascertainment bias, as they provide context to marginalized
individuals with a desire to speak about their symptoms and an implicit understanding that they
share a profound commonality with their audience: their diagnosis. Thus, the experiences they
report with regard to their symptoms and the negative impact of their disease on their QOL may
be unintentionally amplified.
An early study of characteristics of individuals who participate in online support groups
showed that chronic conditions were particularly drawn to online support groups (Davidson et
al., 2000). The internet, no doubt, can be particularly useful in bringing together those who suffer
from rare and debilitating conditions, and online forums appear to be more oriented around
conditions which are poorly understood and somewhat overlooked by the medical community,
especially non-life-threatening conditions such as CMT1A and HNPP. Virtual support can be
especially attractive to those whose disability impairs mobility (Davidson et al., 2000), which
may explain the higher prevalence of support groups for CMT1A, a condition which is more
likely to cause widespread functional impairment and likely to be more frequently diagnosed
when compared to HNPP. The larger number of available support groups for patients with
CMT1A is likely also a result of CMT1A being more commonly diagnosed than HNPP. The
Davidson study also sought to clarify whether support-seeking was primarily motivated by
personal, social, or healthcare-induced anxiety. They found that the severity of the disease did
not raise the participation in support groups within that disease, thus suggesting that healthcareinduced anxiety alone cannot be the main reason, which compares to the QOL outcomes of
studies referenced in our introduction showing that severity of physical symptoms had little to do
with the reporting of poorer QOL among the CMT community. The results of the Davidson
17

study were mostly suggestive, noting that the reality of participation motives is a complex
interaction of illness, individual differences, and cultural norms. Demographically, they found
the elderly and women use health care services more extensively than do young adults and men.
However, parallels to our study could not be made as demographics were not assessed in our
questionnaire, and additional analysis of the data on the basis of potential confounders such as
gender, socioeconomic status, education, and cultural background could not be performed. It is
possible that demographic differences between the CMT1A and HNPP cohorts had an influence
on recorded responses.
Question 4 asked a qualitative question with numerical answer selections rather than
using subjective language as previously used in both the SF-36 and the CMT Health Index to
determine how often an individual experienced symptoms. This was an important contribution in
demonstrating that patients with CMT1A are more likely to experience symptoms every day
compared to the subjects with HNPP. The overlap in symptom patterns between the two groups
has already been established, but the frequency of symptoms was the intended target of this
question. Ninety-two percent of the CMT1A group reported experiencing symptoms closer to
“every day” compared to 82% of the HNPP group reporting the same. Although the data of Q4
is congruent with the rest of the survey data in that the CMT1A group is overall more anxious
about their symptoms on a regular basis than the HNPP group, it is surprising to see the high rate
of HNPP individuals reporting that they experience symptoms “every day”. HNPP patients can
also experience chronic symptoms, although usually less severe and with later onset, but the
percentage of patients that have responded to our survey reporting chronic symptoms is quite
high. This finding suggests the possibility that the HNPP patients that participated in our study
happened to be experiencing more frequent, chronic symptoms, possibly bringing to light an
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ascertainment bias. It is possible that involvement in support groups is more attractive to those
HNPP patients that are experiencing symptoms more frequently or have experienced them for a
longer period of time. Determining the demographics, such as age, of the support groups that
participated in this study and using this to further categorize our findings would be an interesting
avenue to explore further.
Question 14 is similar to Q4 in that a lower mean for the CMT1A group compared to the
HNPP group (1.803, 1.869, respectively) means they are more affected by their symptoms.
However, the difference that exists between the two means barely meets statistical significance.
This may be due to the widespread negative impact experienced by both groups as well as the
overlap of symptoms, including the fact that HNPP patients also can experience chronic
symptoms. However, if our HNPP cohort had included more individuals with the intermittent
pattern, it would make sense that the HNPP group results show that they may be more affected
by their disease because they have not had time to acclimate to the volatility and uncertainty of
their condition. This may cause HNPP patients to be more anxious regarding their concern about
the onset of their symptoms when compared to their chronic counterpart.
Based on patient responses to Question 11, the average HNPP patient has been dealing
with their symptoms for a longer period of time from when their symptoms began to their correct
diagnosis. Granted, the difference in means is not much (CMT1A: 4.707317, HNPP: 4.869048),
but it still exists. Previous studies have demonstrated that due to the heterogeneity of clinical
presentation and intermittent pattern of symptoms, some HNPP patients experience a significant
delay in diagnosis. This delay could have a broad impact on their quality of life as they are not
receiving appropriate healthcare management or are unable to put an end to their diagnostic
odyssey. Objectively, data from Q11 is not normally distributed because the spacing between
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each Likert scale option is not uniform. While the mean for the HNPP group was greater than
that of CMT1A group, indicating a longer time from symptom onset to diagnosis in HNPP
patients, it is not statistically significant (p > 0.5787). Again, when ignoring the quantitative
measures, there is still qualitative significance. A different statistical test could have been used
for this subset of data because we know it does not fulfill the assumption of normal distribution.
We chose to uniformly apply the same test to all subsets of data. Re-evaluating the data with a
different statistical test could be a future direction to investigate.
4.2 Limitations: Sample size disparity
The QOL questionnaire received an overwhelming response from CMT1A patients as
compared to HNPP (287 to 84, respectively). Although data can be standardized, the difference
in sample sizes can lead to data results tethering on the edge of a Type I error. However, when
looking at the amount of responses from each group, the disparate sample sizes are reflective of
disparate patient populations as a whole; CMT1A makes up the most common form of hereditary
neuropathies with an average prevalence ranging from 1/2500 to 1/1200, while HNPP is a rare
disorder with a prevalence of about 16 out of 100,000 individuals; the number of responses from
each group reflects the prevalence of the conditions. The small sample sizes were a consequence
of data collection to begin with and was not secondary to missing data nor participant drop-out,
which would have been alternative causes of sample size imbalance; thus, study design is a
factor that can be considered a limitation in that regard.
4.3 Limitations: Ascertainment bias
It is possible that members of the CMT1A support groups could be influencing each other
to direct attention on the debilitating nature of symptoms, thus skewing individualized opinions
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of one’s own experiences. Data from the Anastas study suggests that patients with chronic pain
are influenced by patient and contextual factors when making pain-related and disability
judgments for peers. These judgments may impact patient decision making via peer support
programs and online forums (Anastas, 2019). Another point to consider is the heterogeneity of
HNPP patients; those with symptoms that fall on the more severe or chronic end of the spectrum
may be drawn to support groups, further creating ascertainment bias.
4.4 Limitations: Demographics
Gathering information on the age, gender, and employment of individuals within each
group could have provided additional stratification to data analysis. In the Johnson et al. study, it
was found that as an individual aged, symptom prevalence increased and QOL worsened
significantly. With regard to gender, several themes were more prevalent in women with
CMT1A, including activity limitations, pain, fatigue, hip–thigh weakness, and gastrointestinal
issues (Johnson et al., 2018)
Not including demographic mining questions in the survey limited our study from being
able to analyze the different response rates among individuals identifying within specific
categories, such as religion, ethnicity, gender, age, language preference, and employment.
Further, recruiting solely from established groups and consortiums excludes individuals that
choose not to partake in these groups; these individuals may offer a unique perspective to QOL
outcomes.
4.5 Clinical Implications
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It has been previously demonstrated that physical findings alone, such as the
electrophysiological findings in CMT1A in the Johnston study or severity of symptoms as shown
in the Grider study, do not fully explain worse QOL outcomes. There are confounding social and
psychological factors associated with pain that could be the true reason behind worse QOL
reports.
In the literature, patients with HNPP experience transient, acute symptoms that may or
may not be associated with pain, however, HNPP patients have also reported experiencing
chronic symptoms. Our survey indicates that the participants experience symptoms at a rate that
seems more chronic than intermittent, potentially due to the ascertainment bias created by
recruitment through support groups. With atypical phenotypes arising, an accurate genetic
diagnosis may not be enough to predict a phenotype, raising the importance of implementing
QOL surveys in clinical practice to aid in management of symptoms and in research to ensure
potential therapies are addressing the symptoms affecting the subjects’ QOL. Establishing the
reasons behind differing perceptions in QOL in CMT1A and HNPP patients is vital for
understanding how to improve patient satisfaction and ensure future treatments are directed
toward the symptoms affecting QOL for these patient populations.
As with many diseases, the course of symptoms may present differently for each
individual. Variations in QOL outcomes can be subject to different influences that we need to
understand better if we wish to implement them into practice.
4.6 Research Recommendations
Future research can compare data from this study to that acquired from consortium or
meta-analysis to evaluate effects of data collection practices on analyses (ie. support/interest
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groups vs. consortium vs. smaller university/hospital datasets); this would influence data
collection practices across many fields. Further research is needed to explore sleep disturbances,
overlap in symptoms, complexities of pain and influence of support groups within both CMT1A
and HNPP groups.
Regarding survey design, the subset of data produced in Question 11 could be calculated
using a different statistical test. Alternatively, the design of the question could be reconfigured to
ensure normal distribution so that the Welch’s t-test is the appropriate statistical analysis to
perform on this data.
Expanding the survey to include the patient demographics in order to compare to
previous studies and to better analyze the results of this survey is recommended. Stratification
between age, gender, etc. would aid in determining which factors are truly a result of differences
in diagnosis rather than a result of differences in demographics.
5. Conclusion
Using support groups to gather data is limiting in that there is no clear way to parse out
an experimental control, set up mutually exclusive categories, and use singular causal models.
Support groups lack the structure needed to be recreated in an experiment. Trying to isolate the
hypothesized reason for a particular outcome is challenging with so many variables at play.
Quantitative approaches in some of our questions lacked validity because they failed to
acknowledge environmental, social, and psychological considerations of CMT1A and HNPP
groups. The overlap of chronic symptoms in CMT1A and HNPP demonstrates the importance of
genetic testing for confirming a diagnosis. Question 4 asked a qualitative question with
numerical answer selections rather than using subjective language like in SF-36 to determine
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how often an individual experienced symptoms. In the SF-36 survey, this question was asked and
gave subjective answer choices such as “all of the time”, “most of the time”, “some of the time”,
etc. Our design for this question was paramount in distinguishing how chronic and intermittent
the symptoms are within each group, allowing us to reveal a statistically significant difference.
Qualitative research with the application of quantitative measurements helps summarize
the data collected and reach a generalization based on statistical projections. Gathering an
individual’s perspective while providing descriptive detail that sets quantitative results into their
human context is challenging, but vital in healthcare.
Quality of life assessments can guide how healthcare providers, including general
practitioners, genetic counselors and rehabilitative specialists modify patient management
throughout the diagnostic and treatment processes in order to improve quality of life indicators in
this population. Utilizing surveys, such as the EQ-5D, as well as other more syndrome-specific
surveys, it is possible to identify some aspects of a patient’s health-related quality of life that can
be improved. However, these surveys do not always provide a complete picture for rarer
conditions presenting with varying phenotypes such as the individuals within our survey’s HNPP
group. Implementing more direct, quantifiable questions to a survey may unlock more insight
into QOL outcomes within these groups. It is important in QOL survey studies to take into
account recruitment methods as well as an individual’s symptom load, demographics, and
attitudes to avoid QOL outcomes centered around the discrepancy between an individual’s
perception of his or her ideal state and his or her true state. Because of the unique training in
psychosocial counseling techniques that genetic counselors undergo, we are particularly
equipped to aid in the research efforts focused on quality of life in patients with rare diseases. A
fundamental focus during genetic counseling sessions is to act as a support for patients and
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families as they navigate the medical, social and psychological complexities of their condition
(Cohen, 2010). Further research into and understanding of quality of life indicators that could be
shaping these patients’ everyday lives can facilitate genetic counselors and other healthcare
providers in offering each individual the most relevant referrals, support and guidance.
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Appendix:
Appendix A: Survey
Quality of Life Survey for Individuals with CMT1A and HNPP
Welcome to Our Survey
Thank you for participating in our survey. Your feedback is important.
1. The purpose of this research project is to identify the reasons behind quality of life perspectives of
individuals who have been diagnosed with HNPP or CMT1A. This research project is being
conducted by Caitlin Walsh and Sophia Rodriguez at Sarah Lawrence College. Your participation
in this research study is voluntary. If you decide to participate in this research study, you may
withdraw at any time. If you decide not to participate in this study or if you withdraw from
participating at any time, you will not be penalized.
The procedure involves completing an online survey that will take approximately 10 minutes.
Your responses will be collected anonymously and we do not collect any personal identifying
information throughout the survey. You will not be asked any additional information or follow-up
questions after completion of the survey. The survey questions will be about your personal
experiences as they relate to your diagnosis of HNPP or CMT1A.
All data is stored in a password protected electronic format. The results of this study will be used
for scholarly purposes only and will fulfill the requirements of our thesis.
If you have any questions about the research study, please contact Caitlin Walsh and Sophia
Rodriguez at cwalsh2@gm.slc.edu or srodriguez1@gm.slc.edu. This research has been reviewed
and approved according to Sarah Lawrence College IRB procedures for research involving human
subjects.
ELECTRONIC CONSENT: Please select your choice below.
Clicking on the "agree" button below indicates that:
• you have ready the above information
• you voluntarily agree to participate in the following survey
If you do not wish to participate in the research study, please decline participation by clicking on
the "disagree" button.
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O Agree
O Disagree
2. Which of the following symptoms do you experience? Please check ALL that apply:
❏
❏
❏
❏
❏
❏
❏
❏
❏
❏
❏
❏

Ankle weakness (foot drop, unable to lift the foot at the ankle)
Permanent foot deformity such as high arch, hammertoes, etc.
Leg muscle weakness
Trouble with balance
Loss of proprioception (the brain’s ability to know where the limbs are in space)
Tingling sensation (pins and needles)
Loss of sensation (numbness)
Difficulty with fine motor skills (ex. pressing buttons)
Hand weakness (trouble with grip)
Fatigue (tiring easily)
Pressure palsies (episodes of muscle weakness that resolve with time)
Other (please specify) ____________________________

3. What is your confirmed diagnosis?
❏
❏
❏
❏

Charcot–Marie–Tooth Type 1A (CMT1A)
Hereditary Neuropathy with Liability To Pressure Palsies (HNPP)
Never confirmed
Other (please specify) ______________________________

4. Choose what best describes the pattern of your symptoms:
❏
❏
❏
❏

I experience symptoms everyday - most of my symptoms never go away
I experience symptoms 3-5 times a week
I experience symptoms every other week
I can go about a month or longer without experiencing any symptoms.

5. Do you feel that your overall quality of life is negatively affected by the pattern of your symptoms
associated with your condition?
❏ Yes
❏ No
6. How often do you think about your symptoms when you are NOT experiencing symptoms?
❏
❏
❏
❏
❏
❏

Never
Rarely
Sometimes
Frequently
All the time
I always experience symptoms
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7. I am concerned about symptoms showing up at inconvenient times.
❏
❏
❏
❏
❏

Never concerned
Rarely concerned
Sometimes concerned
Frequently concerned
Always concerned

8. I am concerned that I won’t be able to fulfill my responsibilities at work/school, attend social
events, participate in physical activities, etc… when symptoms arise.
❏
❏
❏
❏
❏

Never concerned
Rarely concerned
Sometimes concerned
Frequently concerned
Always concerned

9. I am concerned about the unpredictable pattern of my symptoms.
❏
❏
❏
❏
❏

Never concerned
Rarely concerned
Sometimes concerned
Frequently concerned
Always concerned

10. I am concerned about my symptoms getting worse.
❏
❏
❏
❏
❏

Never concerned
Rarely concerned
Sometimes concerned
Frequently concerned
Always concerned

11. How long did it take from when you first started experiencing symptoms to when you were given
a diagnosis?
❏
❏
❏
❏
❏
❏
❏

Less than 6 months
About 1 year
2 years
3 to 4 years
5 years
More than 5 years but less than 10 years
10 years or more

12. Do you feel that the number of doctor's visits you have to attend in a year negatively affects your
life?
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❏ Yes
❏ No
13. Were you ever diagnosed with a different condition before being correctly diagnosed with HNPP
or CMT1A?
❏ Yes
❏ No
If yes, which condition: __________________________________________
14. How much has your life been negatively affected by your symptoms?
❏
❏
❏
❏
❏

Very negatively affected
Somewhat negatively affected
Neutral
Not really negatively affected
Not negatively affected at all

15. Have you undergone any surgeries related to the symptoms of your diagnosis?
❏ Yes
❏ No
If yes, what type of surgery: _______________________________________
16. How much have the surgeries you've had improved or worsened your symptoms and quality of
life?
❏
❏
❏
❏
❏

Very much worsened
Somewhat worsened
Neutral
Somewhat improved
Very much improved

Appendix B: Recruitment Email
My name is Sophia Rodriguez and my thesis partner, Caitlin Walsh, and I are second year
students in the Human Genetics Program at Sarah Lawrence College. We are researching the potential
reasons behind the quality of life perspectives of individuals who have been diagnosed with the hereditary
neuropathies, Charcot Marie Tooth (CMT1A) and Hereditary Neuropathy with Liability to Pressure
Palsies (HNPP).
We are emailing to invite you to participate in a survey that will take approximately 10 minutes to
complete. Participation is completely voluntary and you will not be asked to provide any personal

32

identifying information. If you are interested, please click on the link below to access the survey and
additional information.
If you have any questions or concerns, please do not hesitate to contact us at
cwalsh2@gm.slc.edu or srodriguez1@gm.slc.edu or our faculty advisor, Eleanor Griffith, at
eleanor@greygenetics.com.
We greatly appreciate your time and consideration.
Sincerely,
Sophia Rodriguez and Caitlin Walsh

Figure 1:
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Fig. 1 A graphical representation of the difference in means between the two cohorts for Likert-scaled
questions except Q11, which was not normally distributed.

Figure 2:
Likert Scale Questions

CMT1A

HNPP

p-value

Q4:Choose what best
1.091 + 0.372
describes the pattern of your
symptoms

1.262 + 0.642

0.022

Q6 How often do you think
about your symptoms when
you are NOT experiencing
symptoms?

4.470 + 1.544

4.095 + 1.518

0.049

Q7 I am concerned about
symptoms showing up at
inconvenient times.

3.976 + 1.114

3.643 + 1.116

0.018

Q8 I am concerned that I
won’t be able to fulfill my
responsibilities at
work/school, attend social
events, participate in
physical activities, etc…
when symptoms arise.

4.066 + 1.089

3.786 + 1.131

0.046

Q9 I am concerned about the 3.763 + 1.254
unpredictable pattern of my
symptoms.

3.702 + 1.027

0.652

Q10 I am concerned about 4.362 + 0.849
my symptoms getting worse.

4.190 + 0.828

0.099

Q11 How long did it take
from when you first started
experiencing symptoms to
when you were given a
diagnosis?

4.707 + 2.359

4.869 + 2.338

0.579

Q14 How much has your
1.809 + 0.805
life been negatively affected
by your symptoms?

1.869 + 0.708

0.473

34

Q16 How much have the
surgeries you've had
improved or worsened your
symptoms and quality of
life?

3.478 + 1.154

0.0995

3.0 + 1.169

Fig. 2 Sample means, standard deviations for both cohorts. Welch’s two-sample t-test was applied with
alpha-value set to 0.05.

Figure 3:
Binary Questions

CMT1A

HNPP

Q5 Do you feel that your overall
quality of life is negatively
affected by the pattern of your
symptoms associated with your
condition?

87.108%

84.524%

Q12 Do you feel that the number 34.495%
of doctor's visits you have to
attend in a year negatively
affects your life?

20.238%

Q13 Were you ever diagnosed
with a different condition before
being correctly diagnosed with
HNPP or CMT1A?

16.028%

39.289%

Q15 Have you undergone any
48.780%
surgeries related to the symptoms
of your diagnosis?

23.809%

Fig. 3 Absolute counts were used to calculate overall percentages for binary questions in which
participants responded ‘Yes’.

Figure 4:
Likert Scale Questions

CMT1A

Q6 How often do you think 4.519 + 1.523
about your symptoms
when you are NOT
experiencing symptoms?

HNPP

p-value

2.8 + 0.837

0.00828
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Q7 I am concerned about
symptoms showing up at
inconvenient times.

4.0425 + 1.112

3.6 + 0.894

0.3339

Q8 I am concerned that I
won’t be able to fulfill my
responsibilities at
work/school, attend social
events, participate in
physical activities, etc…
when symptoms arise.

4.102 + 1.078

2.4 + 0.894

0.0121

Q9 I am concerned about the 3.851 + 1.194
unpredictable pattern of my
symptoms.

3.6 + 0.894

0.5689

Q10 I am concerned about 4.396 + 0.838
my symptoms getting worse.

4.2 + .095

0.7111

Q11 How long did it take
from when you first started
experiencing symptoms to
when you were given a
diagnosis?

4.736 + 2.366

4.6 + 2.608

0.9132

Q14 How much has your
1.770 + 0.799
life been negatively affected
by your symptoms?

2.2 + 0.447

0.0975

Fig. 4 Subgroup analyses of CMT1A subjects whose self-reported pattern of symptoms scored <3
(n=283) and HNPP subjects whose self-reported pattern of symptoms scored >3 (n=5).

Figure 5:
Likert Scale Questions

CMT1A

HNPP

p-value

Q6 How often do you think 4.519 + 1.523
about your symptoms
when you are NOT
experiencing symptoms?

4.084 + 1.509

0.03597

Q7 I am concerned about
symptoms showing up at
inconvenient times.

3.732 + 1.041

0.0324

4.0425 + 1.112
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Q8 I am concerned that I
won’t be able to fulfill my
responsibilities at
work/school, attend social
events, participate in
physical activities, etc…
when symptoms arise.

4.102 + 1.078

3.887 + 1.089

0.1471

Q9 I am concerned about the 3.851 + 1.194
unpredictable pattern of my
symptoms.

3.775 + 1.031

0.5992

Q10 I am concerned about 4.396 + 0.838
my symptoms getting worse.

4.281 + 0.778

0.2898

Q11 How long did it take
from when you first started
experiencing symptoms to
when you were given a
diagnosis?

4.736 + 2.366

4.831 + 2.360

0.7674

Q14 How much has your
1.770 + 0.799
life been negatively affected
by your symptoms?

1.887 + 0.747

0.2573

Fig. 5 Subgroup analyses of CMT1A subjects whose self-reported pattern of symptoms scored <3
(n=283) and HNPP subjects who reported intermittent pressure palsies as one of their symptoms (n=71).
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